Genentech, Inc. is a U.S.-based biotechnology company and member of the Roche Group, headquartered in South San Francisco, California. Founded in 1976, the company is recognized for pioneering recombinant DNA technology and for developing biologic medicines, including monoclonal antibodies and other protein therapeutics. Its research and development focus spans oncology, immunology, neuroscience, ophthalmology, and other serious diseases, supported by large-scale biologics manufacturing and clinical supply operations in the United States.
Genentech’s portfolio includes widely used targeted and immunotherapy medicines such as bevacizumab (Avastin), trastuzumab (Herceptin), rituximab (Rituxan, in collaboration with Biogen), pertuzumab (Perjeta), atezolizumab (Tecentriq), tocilizumab (Actemra), omalizumab (Xolair, with Novartis), alectinib (Alecensa), and ocrelizumab (Ocrevus). The company operates within Roche’s global research, development, and manufacturing network, contributing to advances in biologics, antibody engineering, and precision medicine.